DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02998827 (ClinicalTrials.gov)	November 2016	24/11/2016	Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients		Crohn Disease	Drug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutrition	Sixth Affiliated Hospital, Sun Yat-sen University	NULL	Enrolling by invitation	N/A	N/A	Female	90	N/A	NULL
2	JPRN-UMIN000004427	2007/06/01	01/11/2010	A Prospective Randomized Open Trial to Assess the Efficiency of Infliximab for Crohn's Patients after Intestinal Resection		Crohn's disease	Non-infliximab arm: Conventional medicine is administered, excluding Infliximab, Azathioprine, and 6-Mercaptopurine, to subjects during the study period (for 60 months, maximum). Infliximab arm: Infliximab is administered to subjects during the study period (for 60 months, maximum) together with other conventional medications, such as 5-aminosalicylic acid. Infliximab is administered every 8 weeks to subjects during study period after the start of protocol treatment as a rule. Immunomodulators, such as Azathioprine and 6-Mercaptopurine, are not permitted during the trial.	Lower GI disease, Hyogo College of Medicine	NULL	Complete: follow-up complete	16years-old	65years-old	Male and Female	30	Phase 2;Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02998827
(ClinicalTrials.gov)

November 2016

24/11/2016

Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients

Crohn Disease

Drug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutrition

Sixth Affiliated Hospital, Sun Yat-sen University

NULL

Enrolling by invitation

N/A

Female

N/A

NULL

JPRN-UMIN000004427

2007/06/01

01/11/2010

A Prospective Randomized Open Trial to Assess the Efficiency of Infliximab for Crohn's Patients after Intestinal Resection

Crohn's disease

Non-infliximab arm:
Conventional medicine is administered, excluding Infliximab, Azathioprine, and 6-Mercaptopurine, to subjects during the study period (for 60 months, maximum).

Infliximab arm:
Infliximab is administered to subjects during the study period (for 60 months, maximum) together with other conventional medications, such as 5-aminosalicylic acid. Infliximab is administered every 8 weeks to subjects during study period after the start of protocol treatment as a rule. Immunomodulators, such as Azathioprine and 6-Mercaptopurine, are not permitted during the trial.

Lower GI disease, Hyogo College of Medicine

NULL

Complete: follow-up complete

16years-old

65years-old

Male and Female

Phase 2;Phase 3

Japan